GlassScriptPhysician profile
Madhuri V Mahajan
NPI 1417910704
$2,880.29
in general payments reported to CMS, 2019-2025
23 companies · $33.71 in 2025
The $33.71 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $662 · 2021: $1,042 · 2022: $419 · 2023: $170 · 2024: $93.48 · 2025: $33.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $297.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $500.27 | 2019-2022 | |
| Abbvie INC. | $403.46 | 2021-2025 | |
| Glaxosmithkline, LLC. | $317.31 | 2019-2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $279.83 | 2019-2023 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $228.45 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $144.39 | 2019-2021 | |
| Amarin Pharma, INC. | $119.94 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.98 | 2019-2021 | |
| Lilly USA, LLC | $101.75 | 2019-2021 | |
| Novo Nordisk INC | $91.31 | 2019-2021 | |
| Amgen INC. | $88.83 | 2020-2025 | Krystexxa |
| Merck Sharp & Dohme LLC | $86.48 | 2023 | Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.47 | 2020-2021 | |
| Esperion Therapeutics, INC. | $62.43 | 2021 | |
| Grifols USA, LLC | $51.97 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $44.74 | 2021 | |
| Ucb, INC. | $32.01 | 2020 | |
| Allergan, INC. | $30.53 | 2020 | |
| Horizon Therapeutics Plc | $25.95 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.94 | 2022 | |
| Ibsa Pharma INC. | $21.88 | 2020 | |
| Almatica Pharma LLC | $18.86 | 2021 | |
| Abbott Laboratories | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhuri Mahajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.